Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Change in Accured Expenses (2016 - 2025)

Tvardi Therapeutics' Change in Accured Expenses history spans 13 years, with the latest figure at $787000.0 for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 148.43% to $787000.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $919000.0, a 83.49% decrease, with the full-year FY2025 number at $919000.0, down 83.49% from a year prior.
  • Change in Accured Expenses hit $787000.0 in Q3 2025 for Tvardi Therapeutics, down from $2.9 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for TVRD hit a ceiling of $12.7 million in Q2 2024 and a floor of -$10.2 million in Q1 2024.
  • Historically, Change in Accured Expenses has averaged $758947.4 across 5 years, with a median of $640000.0 in 2022.
  • Biggest five-year swings in Change in Accured Expenses: surged 2089.34% in 2022 and later crashed 1087.19% in 2023.
  • Tracing TVRD's Change in Accured Expenses over 5 years: stood at $2.0 million in 2021, then crashed by 333.09% to -$4.8 million in 2022, then surged by 167.8% to $3.2 million in 2023, then surged by 42.34% to $4.6 million in 2024, then tumbled by 82.92% to $787000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for TVRD at $787000.0 in Q3 2025, $2.9 million in Q2 2025, and -$2.8 million in Q1 2025.